Effects of putative K+ channel blockers on beta-adrenoceptor-mediated vasorelaxation of rat mesenteric artery.
The aim of our study was to investigate the contribution of Ca(2+)-activated K+ channels (KCa channels) and ATP-sensitive K+ channels (KATP channels) to the vasodilator responses to beta-adrenoceptor agonists in the rat isolated mesenteric artery. Isoprenaline and fenoterol concentration-dependently relaxed the phenylephrine-precontracted endothelium-intact arterial rings with 50% inhibitory concentration (IC50) of 0.0314 +/- 0.027 microM (n = 20) and 0.40 +/- 0.04 microM (n = 11), respectively. Charybdotoxin (100 nM) displaced the isoprenaline or fenoterol logarithmic concentration-relaxation curve to the right in the absence and presence of endothelium. In contrast, glibenclamide (10 microM) did not affect the effects of isoprenaline and fenoterol, whereas glibenclamide (3 microM) significantly inhibited the cromakalim-induced vasorelaxation. Neither charybdotoxin (100 nM) nor glibenclamide (10 microM) influenced the vasorelaxation induced by forskolin. Ba2+, a nonselective blocker of K+ channels, inhibited the relaxant effects of isoprenaline and forskolin. These results suggest that KCa but not KATP channels contribute to beta-adrenoceptor-mediated vasodilator response in rat mesenteric artery, and cyclic adenosine monophosphate (cAMP) might not be involved in regulation of the activity of KCa channels.
Huang
Y
Y
Department of Physiology, Faculty of Medicine, Chinese University of Hong Kong, Shatin, NT, Hong Kong.
Kwok
K H
KH
D000255:Adenosine Triphosphate / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D001464:Barium / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D018999:Charybdotoxin / Q000494:pharmacology; D005576:Colforsin / Q000494:pharmacology; D019806:Cromakalim; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005280:Fenoterol / Q000494:pharmacology; D005905:Glyburide / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects* / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D010656:Phenylephrine / Q000494:pharmacology; D026902:Potassium Channel Blockers; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology*
D000318:Adrenergic beta-Agonists; D001578:Benzopyrans; D026902:Potassium Channel Blockers; D011758:Pyrroles; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D019806:Cromakalim; D018999:Charybdotoxin; D005576:Colforsin; D010656:Phenylephrine; D005280:Fenoterol; D001464:Barium; D000255:Adenosine Triphosphate; D000242:Cyclic AMP; D007545:Isoproterenol; D005905:Glyburide; D002118:Calcium